|
| Press Releases |
|
 |
|
| Friday, September 17, 2021 |
|
|
SinoMab, Sinovent and Everest Medicines Announce Licensing Agreement for Global Development and Commercialization of A Next-Generation BTK Inhibitor in Renal Diseases |
| SinoMab BioScience Limited (HKEX 3681.HK, "SinoMab") announced with Suzhou Sinovent Pharmaceuticals Co., Ltd. ("Sinovent") today that they have entered into an exclusive licensing agreement with Everest Medicines (HKEX 1952.HK, "Everest") more info >> |
|
| Monday, January 18, 2021 |
|
|
SinoMab Dosed First Healthy Subject in Phase I Clinical Trial of SN1011 in China |
| SinoMab BioScience Limited ("SinoMab" or the "Company", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases, is pleased to announce that the first healthy subject was successfully dosed in the Phase I clinical trial of SN1011 more info >> |
|
| Monday, November 23, 2020 |
|
|
SinoMab Commenced Construction of its China Headquarters |
| SinoMab BioScience Limited ("SinoMab" or the "Company", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases more info >> |
|
| Thursday, July 23, 2020 |
|
|
SinoMab entered into Strategic Collaboration with D2M |
| SinoMab BioScience Limited ("SinoMab" of the "Company", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases more info >> |
|
| Wednesday, June 10, 2020 |
|
|
SinoMab Announces Clinical Results on its First-in-target SM03 at EULAR 2020 Congress |
| SinoMab BioScience Limited ("SinoMab" or the "Company", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases more info >> |
|
| Friday, January 10, 2020 |
|
|
SinoMab Granted the "Most Popular Newly Listed Company" Award |
| SinoMab BioScience Limited ("SinoMab" or the "Company", together with its subsidiaries, the "Group"; stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases, is pleased to announce that the Group has won the title of the "Most Popular Newly Listed Company" at the 4th Hong Kong Golden Stocks Awards held in Shenzhen. more info >> |
|
| Wednesday, November 20, 2019 |
|
|
Great Potential in RA Therapeutic Market, Sinomab Announces Latest Progress of its Drug Candidate SM03 Phase III Clinical Trial for the Treatment RA |
| SinoMab BioScience Limited ("SinoMab BioScience" or the "Company", together with its subsidiaries, the "Group"; stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases, is pleased to announce its latest progress of SM03 phase III clinical trial for the treatment rheumatoid arthritis. more info >> |
|
| Wednesday, October 30, 2019 |
|
|
SinoMab BioScience Announces Proposed Listing on the Main Board of SEHK |
| SinoMab BioScience Limited ("SinoMab BioScience" or the "Company", together with its subsidiaries, the "Group"; stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
Mitsubishi Power Receives Contract for Large-Scale GTCC Project with 2,800 MW Total Output for Taiwan's Tung Hsiao Power Plant
Sept 5, 2025 21:47 JST
|
|
|
Hitachi announces historic $1 billion USD manufacturing investment to power America's energy future through production of critical grid infrastructure 
Sept 5, 2025 21:00 JST
|
|
|
Fourth Paradigm announces 2025 interim results
Sept 5, 2025 18:25 HKT/SGT
|
|
|
Asia Unicorn Forum Releases 2024 Report: China, India, Israel Top Asian Unicorn Rankings
Sept 5, 2025 11:03 HKT/SGT
|
|
|
CBL International Reports 1H 2025 Results Highlighting Strong Biofuel Growth, Reduced Net Loss, and Improved Gross Profit Margin
Sept 5, 2025 10:36 HKT/SGT
|
|
|
NEC participates in Locked Shields 2025 hosted by the NATO Cooperative Cyber Defence Centre of Excellence
Sept 5, 2025 11:20 JST
|
|
|
LOLC Advanced Tech and Corsair Group Join Forces to Transform Waste into Fuel in Sri Lanka
Sept 5, 2025 07:00 HKT/SGT
|
|
|
TANAKA Announces Executive Appointment
Sept 5, 2025 3:00 JST
|
|
|
The MOU Signing Ceremony cum Seminar Titled "A New Horizon in Film & TV Trading: Web3 x DMP - Reshaping the Cross-Industry Supply Chain" Hosted by eBRAM Concludes Successfully
Sept 4, 2025 22:35 HKT/SGT
|
|
|
Magnum Opus Resorts Launches International Architectural Design Competition for Iconic Costa Rica Retreat
Sept 4, 2025 21:07 HKT/SGT
|
|
|
U.S. Polo Assn. Celebrates Historic Title Sponsorship of 2025 Pacific Coast Open at Santa Barbara Polo & Racquet Club
Sept 4, 2025 19:00 HKT/SGT
|
|
|
HKTDC Export Confidence Index: 3Q25; Exporter optimism rises as global trade tension falls
Sept 4, 2025 17:10 HKT/SGT
|
|
|
Zhejiang Expressway Absorbs and Merges with Oceanking Development: Establishing Dual A+H Platform to Boost Share Price
Sept 4, 2025 15:02 HKT/SGT
|
|
|
Fashion Hong Kong celebrates 10th anniversary, Four local brands present 'A Decade in Design: What is Seen? What is Felt?'
Sept 4, 2025 13:47 HKT/SGT
|
|
|
Honda to Begin Sales of All-new Prelude
Sept 4, 2025 13:20 JST
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
